{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:26:42Z","timestamp":1786717602452,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi J Gastroenterol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/1319-3767.191141","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T02:26:49Z","timestamp":1474943209000},"page":"366","source":"Crossref","is-referenced-by-count":8,"title":["Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori"],"prefix":"10.4103","volume":"22","author":[{"given":"Murat","family":"Kekilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IbrahimK","family":"Onal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynal","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpaslan","family":"Tanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1319-3767.191141-1","first-page":"3","volume-title":"Review article: Natural history and epidemiology of Helicobacter pylori infection","author":"Go","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.191141-2","first-page":"283","volume-title":"Helicobacter pylori: Epidemiology and routes of transmission","author":"Brown","year":"2000","journal-title":"Epidemiol Rev"},{"key":"key-10.4103\/1319-3767.191141-3","first-page":"705","volume-title":", Clemens J.Helicobacter in the developing world","author":"Frenck","year":"2003","journal-title":"Microbes Infect"},{"key":"key-10.4103\/1319-3767.191141-4","first-page":"1175","volume-title":"Helicobacter pylori infection","author":"Suerbaum","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.191141-5","first-page":"355","volume-title":"Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study","author":"Wang","year":"2015","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.191141-6","first-page":"57","volume-title":"Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: A 10-year follow-up study","author":"Tursi","year":"2014","journal-title":"Panminerva Med"},{"key":"key-10.4103\/1319-3767.191141-7","first-page":"642","volume-title":"What is the impact of Helicobacter pylori density on the success of eradication therapy: A clinico-histopathological study","author":"Onal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"key-10.4103\/1319-3767.191141-8","first-page":"646","volume-title":"Management of Helicobacter pylori infection - The Maastricht IV\/Florence Consensus Report","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"key-10.4103\/1319-3767.191141-9","first-page":"10","volume-title":"Prevalence of primary antimicrobial resistance of H.pylori in Turkey: A systematic review","author":"Kocazeybek","year":"2015","journal-title":"Helicobacter"},{"key":"key-10.4103\/1319-3767.191141-10","first-page":"79","volume-title":"Optimal therapy for Helicobacter pylori infections","author":"Rimbara","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.191141-11","first-page":"1123","volume-title":"Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori","author":"Gerrits","year":"2004","journal-title":"J Med Microbiol"},{"key":"key-10.4103\/1319-3767.191141-12","first-page":"747","volume-title":"High Helicobacter pylori resistance rate to clarithromycin in Turkey","author":"Onder","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"key-10.4103\/1319-3767.191141-13","first-page":"9898","volume-title":"Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance","author":"Papastergiou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/1319-3767.191141-14","doi-asserted-by":"crossref","unstructured":"Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802-7.e1.","DOI":"10.1016\/j.cgh.2013.01.008"},{"key":"key-10.4103\/1319-3767.191141-15","first-page":"1","volume-title":"What is the best first choice treatment option for Helicobacter pylori?","author":"Kadayif\u00e7i","year":"2007","journal-title":"Turk J Gastroenterol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:26:34Z","timestamp":1786713994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-3767.191141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["191141"],"URL":"https:\/\/doi.org\/10.4103\/1319-3767.191141","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}